FAIR PHARMA SCORECARD
that access to medicines is a human right
that pharmaceutical companies can do more
that they should be held accountable
The Fair Pharma Scorecard ranks pharmaceutical companies on how well their policies and practices reflect a commitment to human rights principles.
Fair Pharma Scorecard: Covid-19 edition
In a pandemic, no one is safe until everyone is safe. In the early days of the outbreak, billions in public financing were mobilised to support urgently needed research and development on Covid-19 countermeasures. But this public financing did not in practice lead to equitable access to resulting vaccines and therapeutics.
The 2022 Fair Pharma Scorecard ranks 30 different Covid-19 products produced by 26 companies, based on how closely companies chose to adhere to human rights commitments, transparency, international cooperation, and equality, non-discrimination and equity. Click the boxes to see details of how each company scored, or the button below to see the scorecard overview.
What do we mean by "Fair Pharma?"
Pharmaceutical companies produce essential medicines. Governments offer them exclusive rights to incentivise the development of medicines, as medical innovation is in the public interest. In return, pharmaceutical companies have a duty to protect this public interest, and not to use market exclusivity to drive up prices to unsustainable levels or to prevent follow-on innovation. The degree to which they respect this duty of care is the degree to which we consider them to meet ‘fair pharma’ principles.
How is the Scorecard ranked? A detailed explanation of our Fair Pharma criteria, scoring methods, and data collection process.
How can companies improve their behaviour? See our guidance on how pharma companies can better adhere to human rights principles.
Policy recommendations that can improve equitable access to vaccines and therapeutics during Covid-19 .